Haddad TC, Shah MD, Symmans WF, et al.

I-SPY 2 low risk registry: An I-SPY 2 trial sub-study for women with clinically advanced, ER+, HER2- breast cancer and molecular good-prognosis gene signature

.

2015 American Society of Clinical Oncology Annual Meeting

, 

May 29 - June 2

, 

2015

. 

In: 

J Clin Oncol

2015

;

33

 (

15 Suppl.

)

, Abstract No. 

TPS635

.

Tripathy D, Chien AJ, Hylton N, et al.

Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206: Graduation results from the I-SPY 2 Trial

.

2015 American Society of Clinical Oncology Annual Meeting

, 

May 29 - June 2

, 

2015

. 

In: 

J Clin Oncol

2015

;

33

 (

15 Suppl.

)

, Abstract No. 

524

.

Van't Veer L, Esserman L, Sanil A, et al.

DNA repair deficiency biomarkers and identification of ER-positive breast cancer patients who may benefit from veliparib/carboplatin: Results from the I-SPY 2 trial

.

2015 American Society of Clinical Oncology Annual Meeting

, 

May 29 - June 2

, 

2015

. 

In: 

J Clin Oncol

2015

;

33

 (

15 Suppl.

)

, Abstract No. 

521

.

Vidula N, Yau C, Goga A, et al.

Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) expression in primary breast cancer (BC); correlations with clinical characteristics and patient outcomes

.

2015 American Society of Clinical Oncology Annual Meeting

, 

May 29 - June 2

, 

2015

. 

In: 

J Clin Oncol

2015

;

33

 (

15 Suppl.

)

, Abstract No. 

1090

.

Liu MC, Symmans WF, Yau C, et al.

Residual cancer burden (RCB) with veliparib/carboplatin in the I-SPY2 trial

.

2015 San Antonio Breast Cancer Symposium

, 

December 8-12

, 

2015

. 

In: 

Cancer Res

2016

;

76

 (

4 Suppl.

)

, Abstract No. 

P3-07-49

.

Albain KS, Leyland-Jones Brian, Symmans Fraser, et al.

The evaluation of trebananib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY2 Trial

.

2015 San Antonio Breast Cancer Symposium

, 

December 8-12

, 

2015

. 

In: 

Cancer Res

2016

;

76

 (

4 Suppl.

)

, Abstract No. 

P1-14-03

.

Wulfkuhle JD, Yau C, Wolf DM, et al.

Prediction of complete pathologic response to veliparib/carboplatin plus standard neoadjuvant therapy in HER2 negative breast cancer: Exploratory protein pathway marker results from the I-SPY 2 trial

.

2015 San Antonio Breast Cancer Symposium

, 

December 8-12

, 

2015

. 

In: 

Cancer Res

2016

;

76

 (

4 Suppl.

)

, Abstract No. 

P3-07-48

.

Esserman L, Hylton N, , et al.

The role of MRI in evaluating response to neo-adjuvant chemotherapy treatment: The I-SPY experience

.

9th European Breast Cancer Conference

, 

March 19-21

, 

2014

. 

In: 

Eur J Cancer

2014

;

50

 (

2

)

, Abstract No. 

.

Park JW, Liu MC, Yee D, et al.

Neratinib plus standard neoadjuvant therapy for high-risk breast cancer: Efficacy results from the I-SPY 2 TRIAL

.

AACR Annual Meeting 2014

, 

April 5-9

, 

2014

. 

In: 

Cancer Res

2014

;

74

 (

19 Suppl.

)

, Abstract No. 

CT227

.

Bartelink IH, Prideaux B, Hann B, et al.

Spatial distribution of veliparib measured by matrix-assisted laser desorption ionization mass spectrometry in triple-negative breast cancer tumors

.

2014 American Society of Clinical Oncology Annual Meeting

, 

May 30 - June 3

, 

2014

. 

In: 

J Clin Oncol

2014

;

32

 (

26 Suppl.

)

, Abstract No. 

161

.

Glas A, Peeters J, Yau C, et al.

Evaluation of a BRCAness signature as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 trial

.

26th EORTC – NCI – AACR Symposium on Molecular Targets and Cancer Therapeutics

, 

November 18-21

, 

2014

. 

In: 

Eur J Cancer

2014

;

50

 (

6

)

, Abstract No. 

532

.

Fournier MV, Derr A, Margulis A, et al.

Gene expression profiles accompanying phenotypic changes during non-malignant breast epithelial cells acini formation to explain MRI phenotypes

.

2014 San Antonio Breast Cancer Symposium

, 

December 9-13

, 

2014

. 

In: 

Cancer Res

2015

;

75

 (

9 Suppl.

)

, Abstract No. 

P3-06-19

.

Wulfkuhle JD, Yau C, Wolf DM, et al.

Evaluation of HER family protein signaling network as a predictive biomarker for pCR for breast cancer patients treated with neratinib in the I-SPY 2 trial

.

2014 San Antonio Breast Cancer Symposium

, 

December 9-13

, 

2014

. 

In: 

Cancer Res

2015

;

75

 (

9 Suppl.

)

, Abstract No. 

P3-06-15

.

Wolf DM, Yau C, Sanil A, et al.

MammaPrint High1/High2 risk class as a biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL

.

2014 San Antonio Breast Cancer Symposium

, 

December 9-13

, 

2014

. 

In: 

Cancer Res

2015

;

75

 (

9 Suppl.

)

, Abstract No. 

P3-06-25

.

Wolf MD, Yau C, Sanil A, et al.

Evaluation of an in vitro derived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL

.

2014 San Antonio Breast Cancer Symposium

, 

December 9-13

, 

2014

. 

In: 

Cancer Res

2014

;

75

 (

9 Suppl.

)

, Abstract No. 

P3-06-05

.

Yau C, Wolf D, Sanil A, et al.

I-SPY 2 qualifying biomarker evaluation (QBE): The challenge and opportunity for interrogating predicted pathways in an adaptive design biomarker rich trial

.

2014 San Antonio Breast Cancer Symposium

, 

December 9-13

, 

2014

. 

In: 

Cancer Res

2014

;

75

 (

9 Suppl.

)

, Abstract No. 

P3-06-37

.

Yau C, Wolf DM, Sanil A, et al.

MammaPrint High1/High2 risk class as a biomarker of response to neratinib plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL

.

2014 San Antonio Breast Cancer Symposium

, 

December 9-13

, 

2014

. 

In: 

Cancer Res

2014

;

75

 (

9 Suppl.

)

, Abstract No. 

P3-06-29

.

Hylton NM

MR imaging for predicting response to neoadjuvant treatment

.

2013 San Antonio Breast Cancer Symposium

, 

December 10-14

, 

2013

. 

In: 

Cancer Res

2013

;

73

 (

24 Suppl.

)

, Abstract No. 

ES08-3

.

DeMichele A, Yee D, Hylton N, et al.

Rationale of the design of the I-SPY trial

.

Markers in Cancer: A joint meeting by ASCO, EORTC and NCI

, 

November 7-9

, 

2013

. 

In: 

Eur J Cancer

2013

;

49

 (

4 Suppl.

)

, Abstract No. 

SP005

.

Wolf DM, Daemen A, Yau C, et al.

MammaPrint ultra-high risk score is associated with response to neoadjuvant chemotherapy in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

.

San Antonio Breast Cancer Symposium

, 

Deceber 10-14

, 

2013

. 

In: 

Cancer Res

2013

;

73

 (

24 Suppl.

)

, Abstract No. 

P1-08-01

.

Wolf DM, Keck S, Yau C, et al.

Assigning luminal A versus luminal B subtype using the Ki67 index in patients with hormone receptor positive (HR+) breast cancer enrolled in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

.

2013 San Antonio Breast Cancer Symposium

, 

December 10-14

, 

2013

. 

In: 

Cancer Res

2013

;

73

 (

24 Suppl.

)

, Abstract No. 

P1-02-06

.

Wulfkuhle JD, Gallagher RI, Wolf D, et al.

Protein pathway activation mapping of LCM tumor epithelium from I-SPY 1 TRIAL surgical specimens reveals activation of receptor tyrosine kinase drug target signaling networks in the non-responding patient cohort

.

2013 San Antonio Breast Cancer Symposium

, 

December 10-14

, 

2013

. 

In: 

Cancer Res

2014

;

73

 (

24 Suppl.

)

, Abstract No. 

P6-04-01

.

Rugo HS, Olopade O, DeMichele A, et al.

Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL

.

San Antonio Breast Cancer Symposium

, 

December 10-14

, 

2013

. 

In: 

Cancer Res

2013

;

73

 (

24 Suppl.

)

, Abstract No. 

S5-02

.

Clark AS, Chen J, Kapoor S, et al.

Pretreatment Vitamin D Levels and Response to Neoadjuvant Chemotherapy in the I-SPY 1 TRIAL

.

2012 San Antonio Breast Cancer Symposium

, 

December 4-8

, 

2012

. 

In: 

Cancer Res

2012

;

72

 (

24 Suppl.

)

, Abstract No. 

P3-06-10

.

Gluck S, Peeters J, Stork-Sloots L, et al.

Response and long-term outcomes after neo-adjuvant chemotherapy: Pooled dataset of patients stratified by molecular subtyping using MammaPrint and BluePrint

.

2012 American Society of Clinical Oncology Annual Meeting

, 

June 1-5

, 

2012

. 

In: 

Cancer Res

2012

;

72

 (

24 Suppl.

)

, Abstract No. 

P3-06-11

.

Li X, Arlinghaus LR, Chakravarthy AB, et al.

Quantitative DCE-MRI to predict the response of primary breast cancer to neoadjuvant therapy

.

2012 San Antonio Breast Cancer Symposium

, 

December 4-8

, 

2012

. 

In: 

Cancer Res

2012

;

72

 (

24 Suppl.

)

, Abstract No. 

P4-01-03

.

Landis MD, Yau C, Neumeister V, et al.

Multicenter I-SPY 1 TRIAL (CALGB 150007/150012): Breast cancer stem cells are associated with intrinsic chemoresistance and worse survival

.

2012 San Antonio Breast Cancer Symposium

, 

Deceumber 4-8

, 

2012

. 

In: 

Cancer Res

2012

;

72

 (

24 Suppl.

)

, Abstract No. 

P2-10-06

.

Wolf DM, Yau C, Magbanua M, et al.

Gene expression changes associated with response to neoadjuvant chemotherapy are observed early in treatment: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

.

2012 San Antonio Breast Cancer Symposium

, 

2012-12-15

, 

2012

. 

In: 

Cancer Res

2012

;

72

 (

24 Suppl.

)

, Abstract No. 

P2-05-01

.

Wulfkuhle JD, Wolf D, Gallagher RI, et al.

Protein pathway activation mapping of the I-SPY 1 biopsy specimens identifies new network focused drug targets for patients with triple negative tumors

.

2012 San Antonio Breast Cancer Symposium

, 

December 4-8

, 

2012

. 

In: 

Cancer Res

2012

;

72

 (

24 Suppl.

)

, Abstract No. 

P3-04-01

.

Boudreau A, Yau C, Petrillo L, et al.

Activating Mutations in PIK3CA or AKT1 in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)

.

2011 San Antonio Breast Cancer Symposium

, 

December 6-10

, 

2011

. 

In: 

Cancer Res

2011

;

71

 (

24 Suppl.

)

, Abstract No. 

P5-01-05

.

DeMichele A, Yau C, Zhu J, et al.

Comparison of Community and Central Her2 Assessment on Outcome of Neoadjuvant Chemotherapy in the I-SPY Trial

.

2011 San Antonio Breast Cancer Symposium

, 

December 6-10

, 

2011

. 

In: 

Cancer Res

2011

;

71

 (

24 Suppl.

)

, Abstract No. 

P1-06-11

.

Cheang MCU, Prat A, Fan C, et al.

PAM50 HER2−Enriched Subtype Enriches for Tumor Response to Neoadjuvant Anthracyclines/Taxane and Trastuzumab/Taxane Containing Regimens in HER2−Positive Breast Cancer

.

2011 San Antonio Breast Cancer Symposium

, 

December 6-10

, 

2011

. 

In: 

Cancer Res

2011

;

71

 (

24 Suppl.

)

, Abstract No. 

S5-2

.

Gluck S, deSnoo F, Tian S, et al.

Response to Neo-Adjuvant Chemotherapy and Outcomes for I-SPY 1 Patients Stratified by the 70-Gene Prognosis Signature (MammaPrint) and Molecular Subtyping (BluePrint)

.

2011 San Antonio Breast Cancer Symposium

, 

December 6-10

, 

2011

. 

In: 

Cancer Res

2011

;

71

 (

24 Suppl.

)

, Abstract No. 

P1-06-20

.

Hylton NM, Partridge SC, Rosen M, et al.

ACRIN 6698 MR Imaging Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Chemotherapy: A Sub-Study of the I-SPY 2 TRIAL (Investigation of Serial Studies To Predict Your Therapeutic Response with Imaging And moLecular Analysis)

.

2011 San Antonio Breast Cancer Symposium

, 

Deceumber 6-10

, 

2011

. 

In: 

Cancer Res

2011

;

71

 (

24 Suppl.

)

, Abstract No. 

OT2-03-06

.

Mukhtar RA, Lips E, Wesseling J, et al.

Lobular Breast Cancer and NAC: Combined Results from the NKI and I-SPY 1 Trial

.

2011 San Antonio Breast Cancer Symposium

, 

December 6-10

, 

2011

. 

In: 

Cancer Res

2011

;

71

 (

24 Suppl.

)

, Abstract No. 

P1-06-10

.

Li J, Moore D, Yau C, et al.

RANK Expression in Primary Tumor Tissue at the Time of Diagnosis Correlates with Risk of Subsequent Bone Metastases in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)

.

2011 San Antonio Breast Cancer Symposium

, 

December 6-10

, 

2011

. 

In: 

Cancer Res

2011

;

71

 (

24 Suppl.

)

, Abstract No. 

P5-14-0

.

Wolf DM, Yau C, Benz S, et al.

Patient-Specific Integrative Pathway Analysis Using PARADIGM Identifies Key Activities in I-SPY 1 Breast Cancer Patients (CALGB 150007/150012; ACRIN 6657)

.

2011 San Antonio Breast Cancer Symposium

, 

December 6-10

, 

2011

. 

In: 

Cancer Res

2011

;

71

 (

24 Suppl.

)

, Abstract No. 

P1-06-09

.

Mukhtar RA, Hylton N, Rosen M, et al.

MRI Phenotype and Tumor Subtype Affect Breast Conservation Eligibility and MRI Accuracy in the I-SPY 1 Trial (Abstract PD02-05)

.

2011 San Antonio Breast Cancer Symposium

, 

December 6-10

, 

2011

. 

In: 

Cancer Res

2011

;

71

 (

24 Suppl.

)

, Abstract No. 

PD02-05

.

Alvarado MD, Malik A, Wathen KJ, et al.

Predictors of Local Recurrence in High Risk Patients Undergoing Neoadjuvant Chemotherapy in the I-SPY1 Trial (CALGB 150007/12 ACRIN 6657)

.

2010 San Antonio Breast Cancer Symposium

, 

December 8-12

, 

2010

. 

In: 

Cancer Res

2010

;

70

 (

24 Suppl.

)

, Abstract No. 

PD06-03

.

Magbanua MM, Davis SE, Crothers J, et al.

Gene expression in serial biopsies in locally advanced breast cancer patients who failed to respond to neoadjuvant chemotherapy

.

2010 American Society of Clinical Oncology Annual Meeting

, 

June 4-8

, 

2010

. 

In: 

J Clin Oncol

2010

;

28

 (

15_suppl

)

, Abstract No. 

10515

.

Wulfkuhle JD, Lenburg ME, Pierobon M, et al.

Protein signal pathway mapping of human breast cancer from I-SPY: Correlations with response and genomic subtyping

.

, 

, 

2010

. 

In: 

J Clin Oncol

2010

;

28

 (

15 Suppl.

)

, Abstract No. 

10512

.

Campbell MJ, Zhu J, Yau C, et al.

Expression of Genes Associated with the Innate Immune System and Response to Neoadjuvant Chemotherapy in Breast Cancer

.

2010 San Antonio Breast Cancer Symposium

, 

December 8-12

, 

2010

. 

In: 

Cancer Res

2010

;

70

 (

24 Suppl.

)

, Abstract No. 

P5-04-01

.

Mukhtar RA, Hwang ES, Livasy C, et al.

Response of Invasive Lobular Cancers to Neoadjuvant Therapy

.

2010 San Antonio Breast Cancer Symposium

, 

December 8-12

, 

2010

. 

In: 

Cancer Res

2010

;

70

 (

24 Suppl.

)

, Abstract No. 

P2-09-11

.

Cheang MCU, Parker JS, He X, et al.

Hypoxia ( VEGF-S)Signature and CRYABPredict Response to Neoadjuvant Anthracycline/Taxane Containing Chemotherapy within Triple Negative and Unselected Breast Tumors

.

2010 San Antonio Breast Cancer Symposium

, 

December 8-12

, 

2010

. 

In: 

Cancer Res

2010

;

70

 (

24 Suppl.

)

, Abstract No. 

PD07-09

.

Perlmutter J, Parker B, Nixon N, et al.

I-SPY 2 Clinical Trial: Telephone Support Provided by Peer Counselors

.

2010 San Antonio Breast Cancer Symposium

, 

December 8-12

, 

2010

. 

In: 

Cancer Res

2010

;

70

 (

24 Suppl.

)

, Abstract No. 

P2-12-03

.

Symmans WF, Hatzis C, Valero V, et al.

A Genomic Predictor of Survival Following Taxane-Anthracycline Chemotherapy for Breast Cancer

.

2010 San Antonio Breast Cancer Symposium

, 

December 8-12

, 

2010

. 

In: 

Cancer Res

2010

;

70

 (

24 Suppl.

)

, Abstract No. 

PD07-03

.

Perlmutter J, Frank E, LeStage B, et al.

I-SPY 2 Clinical Trial: Advocate Involvement in Protocol, Informed Consent and Patient Support Materials Development

.

2010 San Antonio Breast Cancer Symposium

, 

December 8-12

, 

2010

. 

In: 

Cancer Res

2010

;

70

 (

24 Suppl.

)

, Abstract No. 

P5-07-02

.

Esserman LJ, Perou C, Cheang M, et al.

Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657)

.

2009 American Society of Clinical Oncology Annual Meeting

, 

May 29 - June 2

, 

2009

. 

In: 

J Clin Oncol

2009

;

27

 (

18 Suppl

)

, Abstract No. 

LBA515

.

Hylton N, Blume J, Gatsonis C, et al.

MRI tumor volume for predicting response to neoadjuvant chemotherapy in locally advanced breast cancer: Findings from ACRIN 6657/CALGB 150007

.

2009 American Society of Clinical Oncology Annual Meeting

, 

May 28 - June 2

, 

2009

. 

In: 

J Clin Oncol

2009

;

27

 (

15 Suppl.

)

, Abstract No. 

529

.

DeMichele A, Dunn L, Gimotty P, et al.

Loss of p27 expression and response to neoadjuvant chemotherapy: Results from the I-SPY Trial (CALGB150007/150012, ACRIN6657)

.

2009 American Society of Clinical Oncology Annual Meeting

, 

May 28 - June 2

, 

2009

. 

In: 

J Clin Oncol

2009

;

27

 (

15 Suppl.

)

, Abstract No. 

11091

.

Lin C, Moore D, DeMichele A, et al.

Detection of locally advanced breast cancer in the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) in the interval between routine screening

.

2009 American Society of Clinical Oncology Annual Meeting

, 

May 29 - June 2

, 

2009

. 

In: 

J Clin Oncol

2009

;

27

 (

15 Suppl.

)

, Abstract No. 

1503

.

van't Veer L, Esserman LJ, Linn S, et al.

Evaluation of the effect of screening on the detection of good and poor prognosis breast cancers

.

2009 American Society of Clinical Oncology Annual Meeting

, 

May 28 - June 2

, 

2009

. 

In: 

J Clin Oncol

2009

;

27

 (

15 Suppl.

)

, Abstract No. 

1525

.

Wulfkuhle J, Pierobon M, Laird J, et al.

Discovery of a new phospho-HER2+/FISH- molecular subtype of human breast cancer by functional pathway mapping

.

2009 American Society of Clinical Oncology Annual Meeting

, 

May 28 - June 2

, 

2009

. 

In: 

J Clin Oncol

2009

;

27

 (

15 Suppl.

)

, Abstract No. 

11009

.

Liotta L, Pierobon M, Wulfkuhle J, et al.

Semi-quantitative protein analysis of HER2 and ER levels in human breast cancer reveals broad expression ranges within HER2+ and ER+ phenotypes

.

2009 American Society of Clinical Oncology Annual Meeting

, 

August 15

, 

2009

. 

In: 

J Clin Oncol

2009

;

27

 (

15 Suppl.

)

, Abstract No. 

11014

.

Parker J, Prat A, Cheang M, et al.

Breast Cancer Molecular Subtypes Predict Response to Anthracycline/Taxane-Based Chemotherapy

.

2009 San Antonio Breast Cancer Symposium

, 

December 10-13

, 

2009

. 

In: 

Cancer Res

2009

;

69

 (

24 Suppl.

)

, Abstract No. 

2019

.

van't Veer L, Das D, DeMichele A, et al.

Neoadjuvant Response in the Context of a Biologically Defined Low or High Risk Tumor Has a Different Clinical Consequence, the I-SPY Trial (CALGB 150007/150012, ACRIN 6657)

.

2009 San Antonio Breast Cancer Symposium

, 

December 10-13

, 

2009

. 

In: 

Cancer Res

2009

;

69

 (

24 Suppl

)

, Abstract No. 

2003

.

Wolf D, Das D, Lenburg M, et al.

From the Lab to the Clinic: Gene-Expression Profiles That Are Associated with Mek-Inhibitor Sensitivity In Vitro are Coordinately Co-Expressed in Breast Cancer Biopsy Samples from the I-SPY Trial (CALGB 150007/150012, ACRIN 6657)

.

2009 San Antonio Breast Cancer Symposium

, 

December 10-13

, 

2009

. 

In: 

Cancer Res

2009

;

69

 (

24 Suppl

)

, Abstract No. 

2042

.

Esserman LJ, van't Veer LJ, Perou C, et al.

Biology of breast cancers that present as interval cancers and at young age should inform how we approach early detection and prevention

.

2008 San Antonio Breast Cancer Symposium

, 

December 10-14

, 

2008

. 

In: 

Cancer Res

2008

;

69

 (

2 Suppl.

)

, Abstract No. 

6034

.

Gomez RE, Zakhireh J, Moore D, et al.

Sentinel node biopsy performed in the neoadjuvant setting for breast cancer: results from the I-SPY TRIAL (CALGB 150007/150012 & ACRIN 6657)

.

2008 San Antonio Breast Cancer Symposium

, 

December 10-14

, 

2008

. 

In: 

Cancer Res

2009

;

69

 (

2 Suppl.

)

, Abstract No. 

202

.

Hylton NM, Blume JD, Bernreuter WK, et al.

Comparison of MRI endpoints for assessing breast cancer response to neoadjuvant treatment: preliminary findings of the American College of Radiology Imaging Network (ACRIN) trial 6657

.

2008 San Antonio Breast Cancer Symposium

, 

December 10-14

, 

2008

. 

In: 

Cancer Res

2009

;

69

 (

2 Suppl.

)

, Abstract No. 

6043

.

Livasy C, Carey L, DiMichelle A, et al.

Biomarkers associated with pathologic complete response to neoadjuvant chemotherapy in women with locally advanced breast cancer: results from the I-SPY TRIAL (CALGB 150007/150012; ACRIN 6657)

.

2008 San Antonio Breast Cancer Symposium

, 

December 10-14

, 

2008

. 

In: 

Cancer Res

2008

;

69

 (

2 Suppl.

)

, Abstract No. 

5102

.

Livasy C, Carey L, DeMichele A, et al.

Influence of anthracycline- and taxane-based neoadjuvant chemotherapy on tumor HER2 protein expression in locally advanced breast cancers: results from the I-SPY TRIAL (CALGB 150007/150012 & ACRIN 6657)

.

2008 San Antonio Breast Cancer Symposium

, 

December 10-14

, 

2008

. 

In: 

Cancer Res

2009

;

69

 (

2 Suppl.

)

, Abstract No. 

703

.

McDaniel SA, Krontiras H, CarpenterJr JT, et al.

Safety and effectiveness of dose dense neoadjuvant chemotherapy in patients with stage II/III breast cancer

.

, 

June 1-6

, 

2006

. 

In: 

J Clin Oncol

2006

;

24

 (

18 Suppl.

)

, Abstract No. 

10622

.